Literature DB >> 31537401

Outcomes and Direct Costs of Needle Aponeurotomy, Collagenase Injection, and Fasciectomy in the Treatment of Dupuytren Contracture.

Nels D Leafblad1, Eric Wagner1, Nathan R Wanderman1, Gregory R Anderson1, Sue L Visscher2, Hilal Maradit Kremers3, Dirk R Larson3, Marco Rizzo4.   

Abstract

PURPOSE: The aims of our study were to evaluate the rates and predictors of reinterventions and direct costs of 3 common treatments of Dupuytren contractures-needle aponeurotomy, collagenase injection, and surgical fasciectomy.
METHODS: A retrospective review identified 848 interventions for Dupuytren contracture in 350 patients treated by a single surgeon from 2005 to 2016. The treatments included needle aponeurotomy (NA) (n = 444), collagenase injection (n = 272), and open fasciectomy (n = 132). We collected information on demographics, contracture details, and comorbidities. Outcomes included reintervention rates, time to reintervention, and direct cost of treatments. Standardized costs were calculated by applying 2017 Medicare reimbursement to professional services and cost-to-charge ratios to hospital charges.
RESULTS: Demographics were similar among the 3 treatment groups. The fifth finger was the most commonly affected digit including 43% of the NA, 60% of the collagenase, and 45% of the fasciectomy groups. The 2-year rates of reintervention following NA, collagenase, and fasciectomy were 24%, 41%, and 4%, respectively, and the 5-year rates were 61%, 55%, and 4%, respectively. Younger age and severity of preintervention proximal interphalangeal (PIP) joint contracture were predictive of reintervention in the NA and collagenase groups. The standardized direct costs for NA, collagenase, and fasciectomy were $624, $4,189, and $5,291, respectively. Including all reinterventions, the cumulative costs per digit following NA, collagenase, and surgery at 5 years were $1,540, $5,952, and $5,507, respectively.
CONCLUSIONS: Treatment with collagenase resulted in the highest rate of reintervention at 2 years, comparable reintervention rates to NA at 5 years, and the highest cumulative costs. The NA was the least expensive and resulted in longer duration before reintervention compared with collagenase. More severe PIP joint contractures and younger age at time of initial intervention were predictive of reintervention after collagenase and NA. Fasciectomy has a high initial cost but the lowest reintervention rate. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic IV.
Copyright © 2019 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Collagenase; Dupuytren; fasciectomy; needle aponeurotomy

Year:  2019        PMID: 31537401     DOI: 10.1016/j.jhsa.2019.07.017

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  5 in total

1.  Percutaneous Needle Fasciotomy versus Collagenase Injection for Dupuytren's Contracture: A Systematic Review of Comparative Studies.

Authors:  Takashi Hirase; Rishi Suresh; Michael O Cotton; Alex Han; Matthew B Burn; Joshua D Harris; Shari R Liberman
Journal:  J Hand Microsurg       Date:  2020-12-31

2.  The CeCORD-J study on collagenase injection versus aponeurectomy for Dupuytren's contracture compared by hand function and cost effectiveness.

Authors:  Michiro Yamamoto; Hideo Yasunaga; Ryosuke Kakinoki; Naoto Tsubokawa; Akimasa Morita; Katsumi Tanaka; Akinori Sakai; Toshikazu Kurahashi; Hitoshi Hirata
Journal:  Sci Rep       Date:  2022-05-31       Impact factor: 4.996

3.  Real-world Medicare Healthcare Costs of Patients with Dupuytren's Contracture Treated with Collagenase or Fasciectomy.

Authors:  Vladimir Zah; Filip Stanicic; Jane Ruby; Djurdja Vukicevic; David Hurley
Journal:  Plast Reconstr Surg Glob Open       Date:  2022-08-18

4.  Healthcare Costs and Resource Use of Patients with Dupuytren Contracture Treated with Collagenase Clostridium Histolyticum or Fasciectomy: A Propensity Matching Analysis.

Authors:  Vladimir Zah; Jovana Pelivanovic; Simona Tatovic; Djurdja Vukicevic; Martina Imro; Jane Ruby; David Hurley
Journal:  Clinicoecon Outcomes Res       Date:  2020-11-04

5.  A Personalized Approach to Treat Advanced Stage Severely Contracted Joints in Dupuytren's Disease with a Unique Skeletal Distraction Device-Utilizing Modern Imaging Tools to Enhance Safety for the Patient.

Authors:  Wibke Müller-Seubert; Aijia Cai; Andreas Arkudas; Ingo Ludolph; Niklas Fritz; Raymund E Horch
Journal:  J Pers Med       Date:  2022-03-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.